Comparison of the Effects of Different Routes of Antipsychotic Administration on Pharmacokinetics and Pharmacodynamics

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 16, 2003, Pages 18-23

  Ereshefsky, Larry ^a,b,d,e   Mascarenas, Cynthia A ^b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b San Antonio State Hospital   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d CALIFORNIA CLINICAL TRIALS   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; COPOLYMER; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; FLUPENTIXOL; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; KETONE DERIVATIVE; LONG ACTING DRUG; MICROSPHERE; NEUROLEPTIC AGENT; PALIPERIDONE; POLYGLACTIN; RACLOPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SESAME SEED OIL; TIOTIXENE;

CLINICAL PROTOCOL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INJECTION; MICROENCAPSULATION; MOTOR DYSFUNCTION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; METABOLIC CLEARANCE RATE; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0347146032     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Kane JM. Dosing issues and depot medication in the maintenance of schizophrenia. Int Clin Psychopharmacol 1995;10(suppl 3):65-71
2. Marland GR. Atypical neuroleptics: autonomy and compliance? J Adv Nurs 1999;29:615-622
3. Kemp RA, David AS. Insight and adherence to treatment in psychotic disorders. Br J Hosp Med 1995;54:222-227
4. Remington GJ, Collins A. Video workshop: an educational intervention to enhance compliance in schizophrenia. In: Research Program and Abstracts of the 53rd Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services; Oct 10-14, 2001; Orlando, Fla
5. Lam YWF, Velligan D, Ereshefsky L, et al. Intra-individual variability in plasma concentrations as an indicator of adherence in schizophrenia. Presented at the 42nd annual meeting of the New Clinical Drug Evaluation Unit; June 10-13, 2002; Boca Raton, Fla
6. Battaglia J. Compliance with treatment in schizophrenia. Presented at the 53rd meeting of the American Psychiatric Association Institute on Psychiatric Services; Oct 11, 2001; Orlando, Fla
7. Ereshefsky L, Saklad SR, Tran-Johnson T, et al. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacol Bull 1990;26:108-114
8. Ereshefsky L, Saklad SR, Jann MW. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45:50-58
9. Ereshefsky L. Haldol decanoate [promotional materials]. Raritan, NJ: McNeil Pharmaceuticals; 1988
10. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994;89(suppl 382):11-15
11. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
12. McEvoy JP. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 1986;27:327-335
13. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:189-192
14. 2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch Gen Psychiatry 1997;54:953-958
15. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
16. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38:S80-S88
17. Aravagiri M, Yuwiler A, Marder S. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998;139:356-363
18. Lasser RA, Ramstack JM, Grandolfi GP, et al. Long-acting injectable risperidone (Risperdal Consta): manufacture using Medisorb microsphere technology, pharmacokinetics, and injection-site assessments [poster]. Presented at the 155th annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa
19. Rasmussen M, Vermeulen A, Eerdekens M, et al. Kinetics and safety of a novel long-acting risperidone formulation. Presented at the 11th World Congress of Psychiatry; Aug 6-11, 1999; Hamburg, Germany
20. Eerdekens M, Rasmussen M, Vermeulen A, et al. Kinetics and safety of a novel risperidone depot formulation [poster]. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco, Mexico
21. Fleischhacker WW, Eerdekens M, Xie Y, et al. Long-term safety and efficacy of Risperdal Consta, a long-acting injection formulation of risperidone [poster]. Presented at the 40th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii
22. Gefvert O, Nyberg S, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of a new long-acting injectable formulation of risperidone in patients with schizophrenia [poster]. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
23. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869-875